论文部分内容阅读
目的评价多西他赛联合奥沙利铂同步化放疗治疗局部晚期非小细胞肺癌疗效和不良反应。方法将74例晚期非小细胞肺癌患者随机分为两组,单纯放疗组38例采用放射治疗2Gy/次,5次/周,总剂量65～70Gy;同步化放疗组36例,放疗方案与单纯放疗组相同,同时以多西他赛60mg,d1、d8,奥沙利铂100mg,d2、d9方案,每3周1疗程,共2疗程,放疗结束后4周再以原方案连续化疗2～4疗程。结果同步化放疗组和单纯放疗组有效率分别为88.9%和65.8%(P=0.00),中位生存期分别为25.5个月和13.1个月,两组1、2、3年生存率分别为75.0%、63.9%、38.9%和60.5%、34.2%、18.4%(P=0.041);同步化放疗组白细胞降低、放射性肺炎反应发生率显著高于单纯放疗组(P=0.00),同步化放疗组有Ⅰ～Ⅱ度的外周神经炎发生。结论多西他赛联合奥沙利铂同步化放疗治疗晚期非小细胞肺癌疗效明显优于单纯放疗,是较为有效、不良反应可以耐受的非小细胞肺癌治疗方法。
Objective To evaluate the efficacy and adverse reactions of docetaxel combined with oxaliplatin in the treatment of locally advanced non-small cell lung cancer. Methods 74 patients with advanced non-small cell lung cancer were randomly divided into two groups. Radiotherapy was given in 38 patients in radiotherapy alone for 2 Gy / time, 5 times / week for a total dose of 65-70 Gy. In the synchronized radiotherapy group, 36 patients were treated with radiotherapy alone, The same radiotherapy group, while docetaxel 60mg, d1, d8, oxaliplatin 100mg, d2, d9 regimen every 3 weeks 1 course of treatment, a total of 2 courses, 4 weeks after the end of radiotherapy and then the original regimen of continuous chemotherapy 2 ~ 4 courses. Results The effective rates of synchronized radiotherapy and radiotherapy alone were 88.9% and 65.8%, respectively (P = 0.00). The median survival time was 25.5 months and 13.1 months respectively. The 1, 2 and 3-year survival rates were 75%, 63.9%, 38.9% and 60.5%, 34.2% and 18.4% respectively (P = 0.041). The incidences of leukopenia and radiation pneumonitis were significantly higher in patients treated with synchronized radiotherapy than those treated with radiotherapy alone (P = 0.00) Group Ⅰ ~ Ⅱ degree of peripheral neuritis occurred. Conclusions Docetaxel combined with oxaliplatin simultaneous radiotherapy is superior to radiotherapy alone in the treatment of advanced non-small cell lung cancer. It is a more effective and tolerable non-small cell lung cancer treatment.